U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) Posted on October 13, 2023October 13, 2023 by KBD Admin
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11 Posted on October 6, 2023December 5, 2023 by KBD Admin
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Posted on October 2, 2023October 2, 2023 by KBD Admin
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis Posted on October 2, 2023October 2, 2023 by KBD Admin
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease Posted on October 2, 2023October 25, 2023 by KBD Admin
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria Posted on September 27, 2023September 28, 2023 by KBD Admin
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD Posted on September 27, 2023September 28, 2023 by KBD Admin
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia Posted on September 15, 2023September 18, 2023 by KBD Admin
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics Posted on September 5, 2023September 6, 2023 by KBD Admin
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock Posted on August 15, 2023August 29, 2023 by KBD Admin
